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Case Reportsremains conventional surgical reoperation. High-risk pa-
tients, however, may not tolerate reoperations. The intro-
duction of catheter-based valve implantation has produced
a new option of a valve-in-valve approach to failing bio-
prostheses.2 Without the anatomic difficulties associated
with transcutaneous valve implantation in a native mitral
annulus or a preexisting mitral annuloplasty ring, perfor-
mance of theMVinV procedure is relatively straightforward
because of the circular bioprosthesis sewing ring, which
serves as an excellent landing zone for the transcutaneous
valve stent.
Cheung and colleagues3 reported a small series of 11 pa-
tients (mean Society of Thoracic Surgeons score of 16%)
with symptomatic mitral prosthetic valve dysfunction
who underwent transapical MVinV. The success rate was
100%, with no 30-day mortality. Nine patients were alive
and in New York Heart Association class I or II at a median
follow-up of 357 days.3 Similarly, Seiffert and associates4
reported on 6 high-risk patients (EuroSCORE of 33%)
who underwent MVinV. Implantation was successful in
all patients, with reduction of the transvalvular gradients
and median regurgitation from grade 3 to 0. All patients
in these studies received a balloon-expandable bovine
SAPIEN valve. Despite the fact that Seiffert and associates4
reported postoperative complications in 3 patients, this
approach remains acceptable for high-risk patients with
a failed bioprosthetic MV. As this case report demonstrates,
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The Journal of Thoracic and Caeven during the same procedure for patients at very high
risk requiring reoperative double valve replacement.5 The
unique aspect of this case report is that the patient had un-
dergone a previous TA-AVI procedure. Despite the fact
that the apex had previously been used for a TA-AVI oper-
ation, we did not have any difficulties with mobilization or
cannulation of the apex during the MVinV procedure.
With a growing need for reoperative MV replacement for
bioprosthetic structural valve deterioration, transcatheter
MVinV placement has become as an alternate option. Al-
though the evidence for this approach is limited to a few
case reports and small case series, it appears to be a feasible,
safe, and promising approach in a select patient population.References
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Vigneshwar Kasirajan, MD,a Richmond, VaAllograft failure may limit survival after heart transplant
(HTx). For many patients with primary graft failure or
chronic allograft vasculopathy retransplantation is the
only treatment option. However, presensitization and lim-
ited donor heart availability may prolong wait times.Because allograft failure frequently manifests as biventric-
ular dysfunction, left ventricular assist devices (LVADs)
often provide inadequate support. Biventricular assist
device support has been used successfully in the past,1 but
remains challenging due to anatomic constraints with small
ventricles. The total artificial heart (TAH) (Syncardia, Inc,
Tucson, Ariz) overcomes these limitations and can success-
fully support patients with allograft failure.2 We present our
experiencewith 5 patients who presented with allograft fail-
ure and were supported with a TAH.CLINICAL SUMMARY
Patient characteristics are described in Table 1. The pa-
tients’ ages ranged from 19 to 61 years, and 3 were men.
The time from transplantation to TAH placement wasrdiovascular Surgery c Volume 145, Number 2 e21
TABLE 1. Patient characteristics and outcomes after total artificial heart (TAH) placement
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (y) 19 61 44 42 49
Sex Male Male Female Female Male
Etiology of HF Muscular
dystrophy related
Ischemic
cardiomyopathy
Postpartum
cardiomyopathy
Nonischemic
cardiomyopathy
Viral
cardiomyopathy
Time since HTx
to TAH
114 d 1 d 18 y 4 d 7 y
HTx technique Bicaval Bicaval Biatrial Bicaval Biatrial
Etiology of
graft failure
Acute rejection Primary graft failure Allograft vascuopathy Primary graft failure Allograft vasculopathy
Days on TAH 32 79 225 425 346
Repeat HTx No No Yes No No
Outcome Died of delayed bleeding Died of sepsis Alive Alive Alive
HF, Heart failure; HTx, heart transplant.
Case Reports1 day to 18 years. Etiology of graft failure was primary graft
failure (2 patients), acute rejection in 1 patient, and severe
chronic allograft vasculopathy in 2 patients. Despite maxi-
mal medical treatment with multiple inotropes, mechanical
circulatory support with intra-aortic balloon pump, and/or
extracorporeal membrane oxygenation, all patients had
evidence of multisystem organ failure (MSOF).
Following redo sternotomy and dissection patients were
placed on cardiopulmonary support via arterial cannula in
the ascending aorta and venous drainage via bicaval cannu-
lation. Biventricular excision was performed with a small
rim of ventricular tissue left on the atrial cuffs. Following
TAH implantation, immunosuppression was withdrawn
completely in all patients.
The duration of TAH support ranged from 32 to 425 days
and end organ recovery was observed in all but 1 patient
who died of sepsis after 79 days of TAH support. One
patient experienced catastrophic bleeding from the aortic
suture line on postoperative day 23 that led to acute deteri-
oration and rapidMSOF leading to death. Of the 3 surviving
patients, 1 received HTx after 225 days of TAH support. At
the time of HTx the previous atrial tissue appeared viable
without any evidence of gross necrosis or fibrosis despite
the absence of immunosuppression. She is doing well 7
months after undergoing retransplantation.
The remaining 2 patients were sent home with a portable
driver for the TAH for a total of 382 days. Treatments for
markedly elevated panel reactive antibodies are extending
the transplantation wait times.DISCUSSION
Primary graft failure accounts for 40% of deaths in first 30
days after HTx3 and coronary vasculopathy limits long-term
allograft survival. Steps designed to optimize and utilize
more potential heart donors, including accepting hearts
from donors aged 55 years and older, also increase risk of
allograft vasculopathy.3 Mechanical circulatory support fore22 The Journal of Thoracic and Cardiovascular Surggraft failure hasprimarily relied onLVADs. Small ventricular
chambers and associated thrombi limit the technical aspect of
LVAD implantation. Because allograft failure is often
a biventricular problem, outcomes with LVAD support alone
havebeenpoor.4Most available biventricular support devices
require graft ventricles to be in place, and thus patients need
ongoing immunosuppression.Thehighdoses of immunosup-
pressive drugs used in these very ill patients can adversely
affect wound healing, susceptibility to sepsis, and increase
the risk of MSOF—all leading to poor outcomes. Once
a TAH is implanted we discontinue all immunosuppressants.
Although donor atria from previous transplantations are left
in place, it is of concern that lack of ongoing immunosuppres-
sion would lead to atrial wall necrosis, predisposing to atrial
suture line dehiscence from potential tissue necrosis. We did
not find this to be a problem in any of our patients. At the time
of repeat transplantation, we followed bicaval heart implan-
tation technique. Atria from the previous transplantation
appeared viable with no evidence of necrosis.
The TAH is a biventricular support system and can restore
a cardiac output of up to 10 L/minute. This helps reverse the
MSOF often encountered in patients with advanced graft
failure.5 We observed this in all but 1 patient. Bleeding, sep-
sis, and sensitization present challenges in the postoperative
care of these patients. The latter 3 of our patients survived
the initial biventricular failure with a more expedient TAH
implant. After successful recoverywewere able to discharge
them to home with a portable driver.
For failing cardiac allografts without potential for recov-
ery, we find the TAH to be an effective bridge for patients
eligible for retransplantation. However, overcoming issues
related to bleeding, infections, and sensitization continue
to be challenges after TAH implantation.References
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(CC-TGA) is a rare anomaly that is seen in fewer than
0.5% of patients with clinically evident congenital heart
disease. Failure of the systemic ventricle (morphologi-
cally right ventricle [RV]) is the main cause of heart fail-
ure.1 Heart transplant is the treatment of choice for most
patients with CC-TGAwho are in end-stage heart failure.
Ventricular assist devices (VADs) may become necessary
to deal with progressive decline of end-organ function
during the wait for an appropriate donor. Patients with
CC-TGA present unique challenges for VAD implanta-
tion and management.
CLINICAL SUMMARY
A 66-year-old man with a diagnosis of CC-TGAwas seen
at an outside hospital for worsening shortness of breath. He
had shown slow progression to NewYork Heart Association
functional class IV symptoms during the previous 8 years.
His medical history was also significant for chronic atrial fi-
brillation and dyslipidemia. He was started on a continuous
milrinone infusion of 0.3 mg/(kg $ min) and transferred to
our hospital for possible VAD placement.
The patient’s preoperative hemodynamic values with
milrinone infusion were as follows: blood pressure,
110/65 mm Hg; heart rate, 90 beats/min; cardiac index,1.65 L/(min $ m2), and pulmonary vascular resistance,
129 dynes/(s $ cm5). After induction of general anesthesia,
transesophageal echocardiography (TEE) was performed.
The moderator band and the inferior insertion of the
atrioventricular valve leaflets helped to identify the left-
positioned ventricle as the morphologically RV and the
associated valve as the tricuspid valve. The tricuspid valve
was trileaflet, with a large prolapsed septal leaflet, a small
anterior leaflet, and a cleft posterior leaflet. The tricuspid
annulus was dilated to 49 mm, and color flowDoppler ultra-
sonography demonstrated severe tricuspid regurgitation.
The ejection fraction of the morphologically RV was only
20%, with RVend-diastolic diameter of 8.7 cm. The pulmo-
nary ventricle (morphologically left ventricle) function was
nearly normal, with an ejection fraction of 50%.
A standard sternotomywas performed. The systemic aorta
and right atrium were cannulated, and cardiopulmonary by-
passwas established.Because of concerns that themoderator
band andmultiple papillarymuscles in theRVmight obstruct
the VAD inflow cannula, an 18-gauge angiocatheter was in-
serted into the RV, and agitated saline solution was injected
to determine the optimal angle for the VAD inflow cannula.
When the tip of the angiocatheter was found to be in the mid
RV cavity without obvious obstruction, the sewing ring was
sutured and ventriculotomy was then performed with the
punch. On visual inspection, there were no significant cross-
ing fibers. A HeartWare HVAD (HeartWare, Inc, Miramar,
Fla) was then inserted with its center in the predetermined
site. The outflow cannula was then anastomosed to the sys-
temic aortawith a partially occluding aortic clamp. TEE ver-
ified that the VAD inflow cannula was positioned parallel to
the interventricular septum without significant obstruction.
Initially, a pump flow of 3.5 L/min was achieved after wean-
ing off cardiopulmonary bypass. The device was positioned
in the mediastinum, and the outflow graft was placed in the
pericardial well (Figures 1 and 2).
Postoperatively, the patient did well hemodynamically
and had good pump performance. On postoperative dayrdiovascular Surgery c Volume 145, Number 2 e23
